They found that programmed cell death-1 (PD-1) on immune cells (iPD-L1) was associated with favorable prognosis, but PD-L1 expression on tumour cells (tPD-L1) has inconsistent outcomes and failed to perform as a useful biomarker (30). The gene discussed is PDCD1; the disease is neoplasm.